Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) and Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.
Insider and Institutional Ownership
7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Indaptus Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indaptus Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Aldeyra Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 231.33%. Given Aldeyra Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Indaptus Therapeutics.
Valuation & Earnings
This table compares Indaptus Therapeutics and Aldeyra Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Indaptus Therapeutics | N/A | N/A | -$20.85 million | ($24.13) | -0.07 |
| Aldeyra Therapeutics | N/A | N/A | -$33.85 million | ($0.57) | -2.91 |
Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Indaptus Therapeutics and Aldeyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Indaptus Therapeutics | N/A | -939.67% | -293.64% |
| Aldeyra Therapeutics | N/A | -63.75% | -41.27% |
Summary
Aldeyra Therapeutics beats Indaptus Therapeutics on 8 of the 11 factors compared between the two stocks.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
